Page 152 - MI-2-3

Microbes & Immunity Characterizing low-grade CNS tumors

34. Van Hooren L, Vaccaro A, Ramachandran M, et al. Agonistic 39. McClellan BL, Haase S, Nunez FJ, et al. Impact of epigenetic
CD40 therapy induces tertiary lymphoid structures but reprogramming on antitumor immune responses in glioma.
impairs responses to checkpoint blockade in glioma. Nat J Clin Invest. 2023;133(2):e163450.
Commun. 2021;12(1):4127.
doi: 10.1172/JCI163450
doi: 10.1038/s41467-021-24347-7
40. Liu Y, Ali H, Khan F, Pang L, Chen P. Epigenetic regulation
35. Tang F, Wang Y, Zeng Y, Xiao A, Tong A, Xu J. Tumor- of tumor-immune symbiosis in glioma. Trends Mol Med.
associated macrophage-related strategies for glioma 2024;30(5):429-442.
immunotherapy. NPJ Precis Oncol. 2023;7(1):78.
doi: 10.1016/j.molmed.2024.02.004
doi: 10.1038/s41698-023-00431-7
41. Wang H, Diaz AK, Shaw TI, et al. Deep multiomics profiling
36. Skouras P, Markouli M, Papadatou I, Piperi C. Targeting of brain tumors identifies signaling networks downstream of
epigenetic mechanisms of resistance to chemotherapy in cancer driver genes. Nat Commun. 2019;10(1):3718.
gliomas. Criti Rev Oncol Hematol. 2024;104:104532.
doi: 10.1038/s41467-019-11661-4
doi: 10.1016/j.critrevonc.2024.104532
42. Ghosh A, Chaudhuri S. Tissue-free non-invasive diagnostic
37. Ghosh K, Ghosh S, Chatterjee U, Bhattacharjee P, methodology for brain tumour: Present scenario and future
Ghosh A. Dichotomy in growth and invasion from low- to direction. Biomedicine. 2019;44(1):39-45.
high-grade glioma cellular variants. Cell Mol Neurobiol. doi: 10.51248/.v44i1.4045
2022;42(7):2219-2234.
43. Heiden T, Castaños-Vélez E, Andersson LC, Biberfeld, P.
doi: 10.1007/s10571-021-01096-1
Combined analysis of DNA ploidy, proliferation, and
38. Hanahan D, Weinberg RA. Hallmarks of cancer: The next apoptosis in paraffin-embedded cell material by flow
generation. Cell. 2011;144(5):646-674. cytometry. Lab Invest. 2019;80(8):1207-1213.
doi: 10.1016/j.cell.2011.02.013 doi: 10.1038/labinvest.3780128

Volume 2 Issue 3 (2025) 144 doi: 10.36922/MI025190040